The Trump administration pledged in its 2018 budget to offer more clarity on use of value-based payment and to foster the exchange of preapproval information between industry and payers, which two industry groups view as tracking with a drug pricing policy slate unveiled by a coalition of drug makers and payers last week. Policy watchers told Inside Health Policy that the administration's vaguely worded promise on value-based pay could signify a move toward shielding such arrangements from anti-kickback and Stark...